profit from every $100 of sales.
$0$100
CNS Pharmaceuticals
$2.89-20.17% today
-55.2% in 1 year
1-year low $2.131-year high $7.84
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What CNS Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$15.9 million of profit last year.
SalesProfit
CNS Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| CNS Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads CNS Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -15 | -19 | -15 | -16 | |
| -15 | -19 | -15 | -16 | |
| -15 | -19 | -15 | -16 | |
| -288,191.21 | -91,068.72 | -466.89 | -35.75 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 13 | 2 | 9 | 9 |
| Cash | 10 | 1 | 6 | 7 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 5 | 6 | 3 | 4 |
| 8 | -4 | 6 | 5 | |
| 0 | 0 | 0 | 0 | |
| -141.2% | – | -180.3% | -257.9% | |
| -187.8% | 425.3% | -240.5% | -350.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11 | -14 | -17 | -14 | |
| 0 | 0 | 0 | 0 | |
| -11 | -14 | -17 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 0 | |
| 1 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 0.7×
- –
- –
- 0.2×
- -327.4%
- -375.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -329.5%
- -96.9%
- -164.6%
- -183.8%
- -353.5%
- –
Growth
- –
- –
- +19.2%
- –
- +1,009.3%
Financial health
- 0.4×
- 0.07
- 3.8%
- -1,049.7×
- 1.98
- 1.98
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
What analysts expect
- Average price target
- $0.50
- Range
- $0.50 – $0.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -7.30 | -5.37 | −35.9% |
| Mar 31, 2026 | -5.09 | -5.09 | +0.0% |
| Nov 14, 2025 | -5.76 | -6.63 | +13.1% |
| Aug 14, 2025 | -6.42 | -9.60 | +33.1% |
| Nov 14, 2024 | -150.06 | -0.10 | −149,960.0% |
| Aug 14, 2024 | -4,033.61 | -3,585.43 | −12.5% |
| May 15, 2024 | -12,304.92 | – | – |
| Apr 1, 2024 | -28,511.40 | -57,000.00 | +50.0% |
News
Reviva Pharmaceuticals GAAP EPS of -$0.17 beats by $0.23Seeking Alpha · Nov 13, 2026Eupraxia Pharmaceuticals reports Q3 resultsSeeking Alpha · Nov 11, 2026Ionis Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 6, 2026ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlookSeeking Alpha · Nov 5, 2026Vertex Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 1, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
66Pass
Philip Fisher
39No pass
Peter Lynch
59No pass
Joel Greenblatt
100Pass
Charlie Munger
34No pass
Terry Smith
31No pass
Questions about CNS Pharmaceuticals
Is CNS Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the CNS Pharmaceuticals AI analysis
What does CNS Pharmaceuticals do?
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. It is in Biotechnology.
Does CNS Pharmaceuticals pay a dividend?
No. CNS Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $2,043 to shareholders by buying back its own shares.
Is CNS Pharmaceuticals stock halal?
No. CNS Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 171% of its market value, at or above the 33% limit. How we check
How has CNS Pharmaceuticals stock done over the past year?
Down 55.2% over the past twelve months, to $2.89. It traded between $2.13 and $7.84 and is 63.1% below its high.
Who are CNS Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with CNS Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.